Summit Therapeutics
SMMT
203 hedge funds and large institutions have $1.65B invested in Summit Therapeutics in 2024 Q4 according to their latest regulatory filings, with 67 funds opening new positions, 75 increasing their positions, 37 reducing their positions, and 26 closing their positions.
158% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 26
103% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 37
22% more funds holding
Funds holding: 166 → 203 (+37)
0.9% more ownership
Funds ownership: 11.66% → 12.56% (+0.9%)
11% less capital invested
Capital invested by funds: $1.85B → $1.65B (-$196M)
32% less call options, than puts
Call options by funds: $36.7M | Put options by funds: $53.9M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$41.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$21.7M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$20.7M |
| 4 |
Millennium Management
New York
|
+$16M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$23.8M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$9.26M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$8.98M |
| 4 |
D.E. Shaw & Co
New York
|
-$7.1M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$6.24M |
SMMT Hedge Fund Activity: Q4 2024 in Review
203 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q4 2024, worth a combined $1.65B — down 11% from $1.85B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new SMMT positions and 26 closed out — a net gain of 41 holders — while 75 added to existing stakes and 37 trimmed.
The largest buyer was State Street, adding an estimated $41.4M. The largest seller was Darwin Global Management, exiting entirely with an estimated $23.8M sold.
- 203 institutional investors held Summit Therapeutics (SMMT) as of Q4 2024, up from 166 in Q3 2024.
- Funds reported $1.65B of Summit Therapeutics stock for Q4 2024, down 11% quarter-over-quarter.
- 67 funds opened new Summit Therapeutics positions in Q4 2024 and 26 closed out, a net change of +41 holders.
- The largest Summit Therapeutics buyer in Q4 2024 was State Street, an estimated $41.4M added.
- The largest Summit Therapeutics seller in Q4 2024 was Darwin Global Management, an estimated $23.8M sold.
Based on aggregated 13F filings for Q4 2024.